Please login to the form below

Not currently logged in
Email:
Password:

Dr Desiree Luthman joins Verona Pharma

She takes up its vice president position

Desiree LuthmanUK-based clinical stage biopharma company Verona Pharma has appointed Dr Desiree Luthman as its vice president of regulatory affairs.

Luthman’s expertise lies in a series of roles leading regulatory affairs teams and strategies for pharmaceutical products spanning from early development to post-approval marketing.

She has also held various regulatory positions for global pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene and AstraZeneca.

Jan-Anders Karlsson, chief executive officer of Verona Pharma, said: “We welcome Desiree to our growing pharma team.

“She has an accomplished track record of working closely with the FDA and EMA on behalf of international healthcare companies to achieve key regulatory milestones.

“Her vast experience will be instrumental as we advance our regulatory plans in the US and Europe under her leadership in our effort to deliver important new therapies to patients with respiratory diseases.”

Prior to her new role in Verona Pharma, Luthman previously directed regulatory activities related to pulmonary disease at Sanofi and led its regulatory team through the FDA approval of dupilumab for atopic dermatitis in the US.

27th June 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Infographics